Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDS-1001 and Allogeneic SCT for High-Risk Myeloid Malignancies
NCT05115630Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mbIL21-expanded natural killer cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants Who Experienced Graft Failure at 28 days. Started Apr 2022; status: completed.
02
Drugs
mbIL21-expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05115630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115630.